Medical Cannabis Patient with Tourette's Maintained Safe Driving Ability
A 28-year-old man with Tourette syndrome and ADHD maintained fitness to drive while using medical cannabis for tic management, based on clinical assessment.
Quick Facts
What This Study Found
A patient with treatment-resistant Tourette syndrome and ADHD who was prescribed medical cannabis maintained his fitness to drive. This addresses the common concern about cannabis-impaired driving in medical cannabis patients who develop tolerance to psychoactive effects.
Key Numbers
1 patient, age 28. Tourette syndrome + ADHD. Medical cannabis treatment. Driving fitness maintained. Treatment-resistant to conventional options.
How They Did This
Case report of a 28-year-old male with Tourette syndrome and comorbid ADHD treated with medical cannabis, with assessment of driving fitness.
Why This Research Matters
Driving restrictions are a major barrier to medical cannabis access, particularly for conditions like Tourette syndrome where cannabis may be the only effective treatment. This case contributes to the evidence that tolerance to driving impairment can develop.
The Bigger Picture
The tension between medical cannabis efficacy and driving safety affects millions of patients worldwide. Case reports like this can inform policy discussions about how to balance treatment access with traffic safety.
What This Study Doesn't Tell Us
Single case report. Cannot generalize to other patients or conditions. Driving fitness assessment methods not detailed. No comparison to driving performance without cannabis. Individual tolerance varies.
Questions This Raises
- ?Do medical cannabis patients generally develop enough tolerance to drive safely?
- ?Should driving restrictions for medical cannabis differ from recreational use?
Trust & Context
- Key Stat:
- Evidence Grade:
- Single case report provides the lowest level of clinical evidence.
- Study Age:
- Recently published case report.
- Original Title:
- Case Report: Effect of medicinal cannabis on fitness to drive in a patient with Tourette Syndrome and ADHD.
- Published In:
- Frontiers in psychiatry, 16, 1595649 (2025)
- Authors:
- Streetz, Charlotte Marie, Szejko, Natalia(8), Pisarenko, Anna(3), Fremer, Carolin, Teske, Jörg, Brunnauer, Alexander, Müller-Vahl, Kirsten R
- Database ID:
- RTHC-07734
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can you drive while using medical cannabis?
This case report showed one patient maintained driving fitness during medical cannabis treatment, likely due to tolerance development. However, individual responses vary and driving laws differ by jurisdiction.
Does cannabis help Tourette syndrome?
This patient had treatment-resistant Tourette syndrome and ADHD for which medical cannabis was prescribed. The case report focused on driving safety rather than tic efficacy.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-07734APA
Streetz, Charlotte Marie; Szejko, Natalia; Pisarenko, Anna; Fremer, Carolin; Teske, Jörg; Brunnauer, Alexander; Müller-Vahl, Kirsten R. (2025). Case Report: Effect of medicinal cannabis on fitness to drive in a patient with Tourette Syndrome and ADHD.. Frontiers in psychiatry, 16, 1595649. https://doi.org/10.3389/fpsyt.2025.1595649
MLA
Streetz, Charlotte Marie, et al. "Case Report: Effect of medicinal cannabis on fitness to drive in a patient with Tourette Syndrome and ADHD.." Frontiers in psychiatry, 2025. https://doi.org/10.3389/fpsyt.2025.1595649
RethinkTHC
RethinkTHC Research Database. "Case Report: Effect of medicinal cannabis on fitness to driv..." RTHC-07734. Retrieved from https://rethinkthc.com/research/streetz-2025-case-report-effect-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.